The Latest Research Progress of Mesenchymal Stem Cells Derived from Multiple Myeloma Patients --Review.
10.19746/j.cnki.issn.1009-2137.2023.04.047
- Author:
Xiao-Sui LING
1
,
2
;
Hai-Ping HE
1
,
3
;
Li-Hua ZHANG
1
,
2
;
Fan LI
1
,
2
Author Information
1. The Affiliated Hospital of Kunming University of Science and Technology
2. Department of Hematology, the First People's Hospital of Yunnan Province, Kunming 650032, Yunnan Province, China.
3. Department of Hematology, the First People's Hospital of Yunnan Province, Kunming 650032, Yunnan Province, China. E-mail: 2398230256@qq.com.
- Publication Type:Journal Article
- Keywords:
bone marrow microenvironment;
cytokines;
mesenchymal stem cells;
multiple myeloma;
signaling pathways
- MeSH:
Humans;
Multiple Myeloma/pathology*;
Osteogenesis;
Mesenchymal Stem Cells;
Cell Differentiation;
Bone Marrow/metabolism*;
Bone Marrow Cells/metabolism*;
Tumor Microenvironment
- From:
Journal of Experimental Hematology
2023;31(4):1233-1236
- CountryChina
- Language:Chinese
-
Abstract:
Multiple myeloma (MM) is a malignant proliferative disease of plasma cells. Bone marrow mesenchymal stem cells (MSC) play an important role in the progression of MM. Compared with normal donor derived MSC (ND-MSC), MM patients derived MSC (MM-MSC) exhibit abnormalities in genes, signaling pathways, protein expression levels and cytokines secreted by themselves. Moreover, the exosomes of MM-MSC can interact with the bone marrow microenvironment. The above reasons can lead to MM cell proliferation, chemoresistance, impaired osteogenic differentiation of MM-MSC, and affect the immunomodulatory capacity of MM patients. In order to further understand the pathogenesis and related influencing factors of MM, this paper reviews the latest research progress of MM-MSC.
